{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:46:28Z","timestamp":1783734388149,"version":"3.55.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Simultaneous treatment of moderate-to-severe upper facial lines is reflective of real-world clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate the efficacy and safety of daxibotulinumtoxinA-lanm for injection (DAXI) for simultaneous treatment of glabellar, forehead, and lateral canthal (LC) lines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>In this open-label, single-arm Phase 2 study, patients (48 enrolled, 94% completed, follow-up 24\u201336 weeks) received DAXI 40U (glabellar), 32U (forehead), and 48U (LC) lines. Key efficacy endpoints: percentages of patients achieving none\/mild wrinkle severity (investigator-rated) for each upper facial line scale at Week 4.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>At Week 4, most patients achieved none\/mild wrinkle severity (investigator-rated): glabellar (96%), forehead (96%), and LC (92%). Median times to loss of none\/mild response (investigator- and patient-rated) among all patients were: 24.6 (glabellar), 20.9 (forehead), and 24.9 (LC) weeks; and 25.0, 24.0, and 28.1 weeks, respectively, among Week-4 responders. At Week 4, most patients reported improvements (Global Aesthetic Improvement Scale: 96%-98%) and high satisfaction rates (85%-98%). Five patients experienced treatment-related adverse events: injection-site erythema (3 patients\/7 events), facial discomfort (2 patients\/2 events), and headache (1 patient\/1 event). No patients experienced eyebrow or eyelid ptosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Simultaneous treatment of upper facial lines with DAXI was well tolerated and demonstrated high response rates, extended duration, and high patient satisfaction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRY<\/jats:title>\n            <jats:p>\n                                 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04259086.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003637","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T08:04:37Z","timestamp":1671437077000},"page":"60-65","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study"],"prefix":"10.1097","volume":"49","author":[{"given":"Jeffrey S.","family":"Dover","sequence":"first","affiliation":[{"name":"SkinCare Physicians, Chestnut Hill, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon D.","family":"Humphrey","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Paul","family":"Lorenc","sequence":"additional","affiliation":[{"name":"Lorenc Aesthetic Plastic Surgery Center, New York, New York;"},{"name":"Department of Plastic Surgery, Lenox Hill Hospital, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Shamban","sequence":"additional","affiliation":[{"name":"Ava MD, Santa Monica, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Gross","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc., Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman G.","family":"Rubio","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc., Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Vitarella","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc., Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.toxicon.2018.11.174","article-title":"Revance's novel peptide excipient, RTP004, and its role in stabilizing daxibotulinumtoxinA (DAXI) against aggregation","volume":"156","author":"Malmirchegini","year":"2018","journal-title":"Toxicon"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","article-title":"DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"145","author":"Carruthers","year":"2020","journal-title":"Plast Reconstr Surg"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/DSS.0000000000002463","article-title":"A large, open-label, phase 3 safety study of DaxibotulinumtoxinA for Injection in glabellar lines: a focus on safety from the SAKURA 3 study","volume":"47","author":"Green","year":"2021","journal-title":"Dermatol Surg"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/DSS.0000000000002531","article-title":"DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study","volume":"47","author":"Fabi","year":"2021","journal-title":"Dermatol Surg"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s40265-021-01631-w","article-title":"Overview of DaxibotulinumtoxinA for Injection: a novel formulation of botulinum toxin type A","volume":"81","author":"Solish","year":"2021","journal-title":"Drugs"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"ojz015","DOI":"10.1093\/asjof\/ojz015","article-title":"The psychological impacts of upper facial lines: a qualitative, patient-centered study","volume":"1","author":"Dayan","year":"2019","journal-title":"Aesthet Surg J Open Forum"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"518e","DOI":"10.1097\/01.prs.0000475758.63709.23","article-title":"Global Aesthetics Consensus: botulinum toxin type A\u2014evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications","volume":"137","author":"Sundaram","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/CCID.S138274","article-title":"Tailored botulinum toxin type A injections in aesthetic medicine: consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone","volume":"10","author":"Anido","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R10-20250731","first-page":"35","article-title":"CME: Re-examining the optimal use of neuromodulators and the changing landscape: a consensus panel update","volume":"19","author":"Kaminer","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/DSS.0000000000001612","article-title":"Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines","volume":"44","author":"De Boulle","year":"2018","journal-title":"Dermatol Surg"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/DSS.0000000000001679","article-title":"Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment of upper facial lines","volume":"44","author":"Hexsel","year":"2018","journal-title":"Dermatol Surg"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/DSS.0000000000000220","article-title":"Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial","volume":"41","author":"Moers-Carpi","year":"2015","journal-title":"Dermatol Surg"},{"issue":"Suppl 1","key":"R14-20250731","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/DSS.0000000000000274","article-title":"Patient-reported outcomes after incobotulinumtoxinA treatment for upper facial wrinkles","volume":"41","author":"Streker","year":"2015","journal-title":"Dermatol Surg"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/DSS.0000000000000357","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines","volume":"41","author":"Carruthers","year":"2015","journal-title":"Dermatol Surg"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","article-title":"Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo","volume":"43","author":"Carruthers","year":"2017","journal-title":"Dermatol Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:06:38Z","timestamp":1753999598000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003637","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]}}}